Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1446

1.

Iodine-123-iomazenil SPECT Revealed Recovery of Neuronal Viability in Association with Improvement in Symptoms Following Treatment for Obstructive Hydrocephalus Due to A Giant Posterior Cerebral Artery Aneurysm: Case Report.

Horiuchi R, Yoshioka H, Kanemaru K, Hashimoto K, Yagi T, Murayama H, Kinouchi H.

World Neurosurg. 2020 Feb 18. pii: S1878-8750(20)30342-9. doi: 10.1016/j.wneu.2020.02.067. [Epub ahead of print] No abstract available.

PMID:
32084622
2.

Bmi-1 Immunohistochemical Expression in Endometrial Carcinoma is Correlated with Prognostic Activity.

Horie K, Iseki C, Kikuchi M, Miyakawa K, Yoshizaki M, Yoshioka H, Watanabe J.

Medicina (Kaunas). 2020 Feb 12;56(2). pii: E72. doi: 10.3390/medicina56020072.

3.

Endoscope-integrated fluorescence video angiography for the surgery of ventrally located perimedullary arteriovenous fistula at craniocervical junction: case report.

Horiuchi R, Kanemaru K, Yoshioka H, Hashimoto K, Murayama H, Yagi T, Ogiwara M, Kinouchi H.

World Neurosurg. 2020 Feb 4. pii: S1878-8750(20)30225-4. doi: 10.1016/j.wneu.2020.01.207. [Epub ahead of print]

PMID:
32032788
4.

T1rho and T2 mapping of ankle cartilage of female and male ballet dancers.

Horiuchi S, Yu HJ, Luk A, Rudd A, Ton J, Kuoy E, Russell J, Sharp K, Yoshioka H.

Acta Radiol. 2020 Feb 6:284185120902381. doi: 10.1177/0284185120902381. [Epub ahead of print] No abstract available.

PMID:
32028774
5.

A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer.

Yoshida K, Kotsuma T, Akiyama H, Yamazaki H, Takenaka T, Masui K, Tsujimoto Y, Murakami N, Uesugi Y, Shimbo T, Yoshikawa N, Yoshioka H, Nakata M, Arika T, Takaoka Y, Tanaka E, Tselis N.

J Contemp Brachytherapy. 2019 Dec;11(6):573-578. doi: 10.5114/jcb.2019.91225. Epub 2019 Dec 25.

6.

Role of salicylic acid glucosyltransferase in balancing growth and defence for optimum plant fitness.

Kobayashi Y, Fukuzawa N, Hyodo A, Kim H, Mashiyama S, Ogihara T, Yoshioka H, Matsuura H, Masuta C, Matsumura T, Takeshita M.

Mol Plant Pathol. 2020 Mar;21(3):429-442. doi: 10.1111/mpp.12906. Epub 2020 Jan 21.

PMID:
31965700
7.

Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.

Aoyama T, Tsunoda T, Kato H, Hagino A, Furutani R, Ito K, Yoshioka H, Nakamura M, Hiraide M, Kawakami K, Kobayashi K, Suzuki K, Ichimura T, Yamaguchi K, Hama T.

J Chemother. 2020 Jan 21:1-7. doi: 10.1080/1120009X.2020.1713507. [Epub ahead of print]

PMID:
31960769
8.

The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice.

Minamizaki T, Nakao Y, Irie Y, Ahmed F, Itoh S, Sarmin N, Yoshioka H, Nobukiyo A, Fujimoto C, Niida S, Sotomaru Y, Tanimoto K, Kozai K, Sugiyama T, Bonnelye E, Takei Y, Yoshiko Y.

Commun Biol. 2020 Jan 16;3(1):30. doi: 10.1038/s42003-020-0754-2.

9.

Disruption of Dhcr7 and Insig1/2 in cholesterol metabolism causes defects in bone formation and homeostasis through primary cilium formation.

Suzuki A, Ogata K, Yoshioka H, Shim J, Wassif CA, Porter FD, Iwata J.

Bone Res. 2020 Jan 2;8:1. doi: 10.1038/s41413-019-0078-3. eCollection 2020.

10.

Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3.

Yoshioka H, Kato T, Okamoto I, Tanaka H, Hida T, Seto T, Kiura K, Tian Y, Azuma H, Yamamoto N.

Future Oncol. 2020 Feb;16(4):49-60. doi: 10.2217/fon-2019-0659. Epub 2020 Jan 10.

11.

Differences in patient-reported outcomes between medial opening-wedge high tibial osteotomy and total knee arthroplasty.

Matsumoto K, Ogawa H, Yoshioka H, Akiyama H.

J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(1):2309499019895636. doi: 10.1177/2309499019895636.

PMID:
31916479
12.

The prevalence of urticaria, hand eczema, atopic dermatitis and asthma among bakers in Japan.

Tashiro T, Sasaki N, Yamamoto K, Yoshioka H, Omoto D, Ohmori S, Okada E, Nakamura M.

Eur J Dermatol. 2019 Dec 1;29(6):663-664. doi: 10.1684/ejd.2019.3665. No abstract available.

PMID:
31903965
13.

Chronotoxicity of Streptomycin-Induced Renal Injury in Mice.

Yoshioka H, Tominaga S, Shinohara Y, Hwang GW, Maeda T, Miura N.

Biol Pharm Bull. 2020;43(1):53-58. doi: 10.1248/bpb.b19-00539.

14.

Luciferase-based HMG-CoA reductase degradation assay for activity and selectivity profiling of oxy(lano)sterols.

Sagimori I, Yoshioka H, Hashimoto Y, Ohgane K.

Bioorg Med Chem. 2020 Feb 1;28(3):115298. doi: 10.1016/j.bmc.2019.115298. Epub 2019 Dec 30.

PMID:
31902650
15.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).

Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y.

J Clin Oncol. 2019 Dec 27:JCO1901494. doi: 10.1200/JCO.19.01494. [Epub ahead of print]

PMID:
31880966
16.

Distal tibial tubercle osteotomy is superior to the proximal one for progression of patellofemoral osteoarthritis in medial opening wedge high tibial osteotomy.

Ogawa H, Matsumoto K, Yoshioka H, Sengoku M, Akiyama H.

Knee Surg Sports Traumatol Arthrosc. 2019 Dec 24. doi: 10.1007/s00167-019-05836-1. [Epub ahead of print]

PMID:
31875232
17.

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T.

Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28.

PMID:
31812890
18.

Comparison between Patients with Chest Infection due to Klebsiella spp. and Streptococcus pneumoniae.

Ishiguro T, Uozumi R, Yoshioka H, Nishida T, Takayanagi N.

Intern Med. 2019 Nov 22. doi: 10.2169/internalmedicine.3531-19. [Epub ahead of print]

19.

Arthroscopic repair of horizontal cleavage meniscus tears provides good clinical outcomes in spite of poor meniscus healing.

Ogawa H, Matsumoto K, Sengoku M, Yoshioka H, Akiyama H.

Knee Surg Sports Traumatol Arthrosc. 2019 Nov 20. doi: 10.1007/s00167-019-05782-y. [Epub ahead of print]

PMID:
31748918
20.

MicroRNA-124-3p suppresses mouse lip mesenchymal cell proliferation through the regulation of genes associated with cleft lip in the mouse.

Suzuki A, Yoshioka H, Summakia D, Desai NG, Jun G, Jia P, Loose DS, Ogata K, Gajera MV, Zhao Z, Iwata J.

BMC Genomics. 2019 Nov 14;20(1):852. doi: 10.1186/s12864-019-6238-4.

21.

Stochastic optimal switching model for migrating population dynamics.

Yoshioka H, Tanaka T, Aranishi F, Izumi T, Fujihara M.

J Biol Dyn. 2019 Dec;13(1):706-732. doi: 10.1080/17513758.2019.1685134.

PMID:
31701818
22.

Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways.

Ichimaru Y, Sano M, Kajiwara I, Tobe T, Yoshioka H, Hayashi K, Ijichi H, Miyairi S.

Transl Oncol. 2019 Dec;12(12):1574-1582. doi: 10.1016/j.tranon.2019.08.010. Epub 2019 Oct 28.

23.

Multiplexing fluorogenic esterase-based viability assay with luciferase assays.

Ohgane K, Yoshioka H, Hashimoto Y.

MethodsX. 2019 Sep 12;6:2013-2020. doi: 10.1016/j.mex.2019.09.008. eCollection 2019.

24.

Improved Characterisation of Vegetation and Land Surface Seasonal Dynamics in Central Japan with Himawari-8 Hypertemporal Data.

Miura T, Nagai S, Takeuchi M, Ichii K, Yoshioka H.

Sci Rep. 2019 Oct 30;9(1):15692. doi: 10.1038/s41598-019-52076-x.

25.

Biphasic adverse effect of titanium nanoparticles on testicular function in mice.

Miura N, Ohtani K, Hasegawa T, Yoshioka H, Hwang GW.

Sci Rep. 2019 Oct 7;9(1):14373. doi: 10.1038/s41598-019-50741-9.

26.

Critical microRNAs and regulatory motifs in cleft palate identified by a conserved miRNA-TF-gene network approach in humans and mice.

Li A, Jia P, Mallik S, Fei R, Yoshioka H, Suzuki A, Iwata J, Zhao Z.

Brief Bioinform. 2019 Oct 7. pii: bbz082. doi: 10.1093/bib/bbz082. [Epub ahead of print]

PMID:
31589286
27.

Cholesterol metabolism plays a crucial role in the regulation of autophagy for cell differentiation of granular convoluted tubules in male mouse submandibular glands.

Suzuki A, Shim J, Ogata K, Yoshioka H, Iwata J.

Development. 2019 Oct 17;146(20). pii: dev178335. doi: 10.1242/dev.178335.

PMID:
31558435
28.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Dec 1;30(12):1978-1984. doi: 10.1093/annonc/mdz399.

PMID:
31553438
29.

[Effects of Tyrosine Kinase Inhibitors on Control of PT-INR in Patients Receiving Warfarin].

Hiraide M, Minowa Y, Nakano Y, Yoshioka H, Suzuki K, Shiga T, Takahashi H, Hama T.

Gan To Kagaku Ryoho. 2019 Sep;46(9):1413-1419. Japanese.

PMID:
31530781
30.

Changes in optical characteristics induced by polymer blending in printed colloidal quantum dots microlasers.

Wan L, Chen C, Zhu J, Nasir KTA, Cui Q, Chen Z, Yoshioka H, Liu W, Oki Y, Li Z.

Opt Express. 2019 Jul 8;27(14):19615-19623. doi: 10.1364/OE.27.019615.

PMID:
31503718
31.

Efficacy of endoscopic sinus surgery for eosinophilic chronic rhinosinusitis with asthma.

Ohta N, Suzuki Y, Ikeda H, Noguchi N, Kakuta R, Suzuki T, Ikeda R, Yamazaki M, Saito Y, Kusano Y, Ishida Y, Shoji F, Yoshioka H, Ono J, Takahashi T, Nakamura Y, Ohno I, Izuhara K.

Allergol Int. 2020 Jan;69(1):144-145. doi: 10.1016/j.alit.2019.08.004. Epub 2019 Sep 5. No abstract available.

32.

Diurnal Variation of Sitagliptin-Induced Pharmacological Effects in C57BL/6J Mice.

Yoshioka H, Hirose Y, Ohishi R, Tominaga S, Torii-Goto A, Park SJ, Miura N, Yoshikawa M.

Biol Pharm Bull. 2019;42(9):1562-1568. doi: 10.1248/bpb.b19-00367.

33.

Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice.

Yoshioka H, Ohishi R, Hirose Y, Torii-Goto A, Park SJ, Miura N, Yoshikawa M.

Obes Res Clin Pract. 2019 Sep - Oct;13(5):505-510. doi: 10.1016/j.orcp.2019.08.001. Epub 2019 Aug 26.

PMID:
31466832
34.

A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).

Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Washio Y, Ishida T, Kogo M, Tomii K, Okuno T, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim YH, Miyakoshi C, Yoshimura K, Hirai T; Kyoto Thoracic Oncology Research Group (KTORG).

Lung Cancer. 2019 Sep;135:175-180. doi: 10.1016/j.lungcan.2019.03.030. Epub 2019 Mar 28.

PMID:
31446992
35.

Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.

Hiraide M, Shiga T, Minowa Y, Nakano Y, Yoshioka H, Suzuki K, Yasuda C, Takahashi H, Hama T.

J Cardiol. 2020 Jan;75(1):110-114. doi: 10.1016/j.jjcc.2019.06.013. Epub 2019 Aug 12.

36.

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.

Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T.

Oncology. 2019;97(6):327-333. doi: 10.1159/000501967. Epub 2019 Aug 14.

PMID:
31412347
37.

Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine.

Tateshita N, Miura N, Tanaka H, Masuda T, Ohtsuki S, Tange K, Nakai Y, Yoshioka H, Akita H.

J Control Release. 2019 Sep 28;310:36-46. doi: 10.1016/j.jconrel.2019.08.002. Epub 2019 Aug 3.

PMID:
31386869
38.

High-Risk Factors for Recurrence of Stage I Lung Adenocarcinoma: Follow-up Data From JCOG0201.

Tsutani Y, Suzuki K, Koike T, Wakabayashi M, Mizutani T, Aokage K, Saji H, Nakagawa K, Zenke Y, Takamochi K, Ito H, Aoki T, Okami J, Yoshioka H, Okada M, Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group (JCOG-LCSSG).

Ann Thorac Surg. 2019 Nov;108(5):1484-1490. doi: 10.1016/j.athoracsur.2019.05.080. Epub 2019 Jul 20.

PMID:
31336067
39.

Retracted: "CITRX thioredoxin interacts with the tomato Cf-9 resistance protein and negatively regulates defence".

Rivas S, Rougon-Cardoso A, Smoker M, Schauser L, Yoshioka H, Jones JD.

EMBO J. 2019 Jun 17;38(12):e102435. doi: 10.15252/embj.2019102435.

40.

Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).

Kimura T, Kawaguchi T, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Asai K, Tanaka H, Yano S, Yamamoto N, Nakanishi Y, Nakagawa K.

Jpn J Clin Oncol. 2019 Oct 1;49(10):947-955. doi: 10.1093/jjco/hyz088.

PMID:
31242302
41.

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.

Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6.

PMID:
31072612
42.

Effects of FABP7 on functional recovery after spinal cord injury in adult mice.

Senbokuya N, Yoshioka H, Yagi T, Owada Y, Kinouchi H.

J Neurosurg Spine. 2019 May 3:1-7. doi: 10.3171/2019.2.SPINE18844. [Epub ahead of print]

PMID:
31051461
43.

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N.

Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2.

44.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

45.

RNAi of the sesquiterpene cyclase gene for phytoalexin production impairs pre- and post-invasive resistance to potato blight pathogens.

Yoshioka M, Adachi A, Sato Y, Doke N, Kondo T, Yoshioka H.

Mol Plant Pathol. 2019 Jul;20(7):907-922. doi: 10.1111/mpp.12802. Epub 2019 Apr 16.

46.

Cyclin A is a reliable proliferation marker in endometrial cancer cell lines.

Horie K, Yamamoto H, Karube K, Takebayashi K, Yoshino H, Yoshioka H, Watanabe J.

Oncol Lett. 2019 May;17(5):4455-4462. doi: 10.3892/ol.2019.10135. Epub 2019 Mar 8.

47.

A stochastic differential game approach toward animal migration.

Yoshioka H.

Theory Biosci. 2019 Nov;138(2):277-303. doi: 10.1007/s12064-019-00292-4. Epub 2019 Apr 11.

PMID:
30972714
48.

Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.

Nanjyo S, Ohgane K, Yoshioka H, Makishima M, Hashimoto Y, Noguchi-Yachide T.

Bioorg Med Chem. 2019 May 15;27(10):1952-1961. doi: 10.1016/j.bmc.2019.03.042. Epub 2019 Mar 26.

PMID:
30940565
49.

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K.

Asia Pac J Clin Oncol. 2019 Aug;15(4):250-256. doi: 10.1111/ajco.13147. Epub 2019 Apr 1.

50.

Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation.

Yamaguchi M, Hirouchi T, Yoshioka H, Watanabe J, Kashiwakura I.

Free Radic Biol Med. 2019 May 20;136:60-75. doi: 10.1016/j.freeradbiomed.2019.03.023. Epub 2019 Mar 26.

PMID:
30926566

Supplemental Content

Loading ...
Support Center